USAQ QHSLab, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 856984 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY213.1%
TTM EPS YoY150.0%
Revenue 3-yr CAGR29.5%
Net income 3-yr CAGR—
Margins
Gross margin68.2%
Operating margin-2.2%
Net margin14.8%
FCF margin—
EBITDA margin0.3%
Returns
ROE97.8%
ROA25.1%
ROIC (approx.)-23.4%
Asset turnover1.70x
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-1.03x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio38.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.69M | $2.13M |
| Cost of revenue | $880,892 | $774,036 |
| Gross profit | $1.81M | $1.36M |
| R&D expense | $484,873 | $294,479 |
| SG&A expense | $439,143 | $276,496 |
| Operating income | $131,244 | $205,738 |
| Interest expense | $237,413 | $465,055 |
| Pretax income | $457,417 | -$259,239 |
| Net income | $457,417 | -$259,239 |
| EBITDA | $221,972 | $352,313 |
| EPS (basic) | 0.04 | -0.03 |
| EPS (diluted) | 0.02 | -0.03 |
| Weighted avg. shares (diluted) | 19.34M | 10.29M |
| Balance sheet | ||
| Cash & equivalents | $636,157 | $157,168 |
| Receivables | $190,610 | $196,089 |
| Inventory | $35,790 | $41,779 |
| Current assets | $883,009 | $420,827 |
| Intangibles | $1.29M | $1.36M |
| Total assets | $2.17M | $1.80M |
| Current liabilities | $449,860 | $2.41M |
| Long-term debt | $90,704 | — |
| Total debt | $90,704 | — |
| Total liabilities | $546,078 | $2.41M |
| Shareholders' equity | $1.62M | -$607,756 |
| Net debt | -$545,453 | — |
| Shares outstanding | 15.03M | 10.81M |
| Cash flow statement | ||
| Operating cash flow | $178,118 | $142,437 |
| Financing cash flow | $300,871 | -$36,851 |
| Depreciation & amortization | $90,728 | $146,575 |
| Stock-based compensation | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.